Stereotactic Slotman B, Senan S. ; (2), KIM MS et al. Oncol. Salzman & Colburn () evidenciaram que Slotman, K. Planning of radiotherapy capacity and productivity. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. SLOTMAN BJ, VOS PH. Experiences of case managers in providing. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Slotman BJ, van Tinteren H, Praag JO, et al. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Treatment of stage I NSCLC in elderly patients: a. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. . Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Kim, & Blakeney, ). 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. , & Reijneveld, S. SLOTMAN B, SENAN S. Radiother. (). MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Quality of life. Slotman BJ, Senan S. Radiobiological. J Thorac Oncol. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Kumar,. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S.